CN110603037A - 普那布林的组合物及其用途 - Google Patents

普那布林的组合物及其用途 Download PDF

Info

Publication number
CN110603037A
CN110603037A CN201880029191.0A CN201880029191A CN110603037A CN 110603037 A CN110603037 A CN 110603037A CN 201880029191 A CN201880029191 A CN 201880029191A CN 110603037 A CN110603037 A CN 110603037A
Authority
CN
China
Prior art keywords
inhibitors
inhibitor
plinabulin
immunotherapy
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880029191.0A
Other languages
English (en)
Chinese (zh)
Inventor
雷蒙·穆汗拉尔
黄岚
乔治·肯尼斯·劳埃德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Publication of CN110603037A publication Critical patent/CN110603037A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880029191.0A 2017-03-13 2018-03-12 普那布林的组合物及其用途 Pending CN110603037A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762470802P 2017-03-13 2017-03-13
US62/470,802 2017-03-13
US201862621528P 2018-01-24 2018-01-24
US62/621,528 2018-01-24
PCT/US2018/022064 WO2018169887A1 (en) 2017-03-13 2018-03-12 Compositions of plinabulin and use thereof

Publications (1)

Publication Number Publication Date
CN110603037A true CN110603037A (zh) 2019-12-20

Family

ID=63522552

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880029191.0A Pending CN110603037A (zh) 2017-03-13 2018-03-12 普那布林的组合物及其用途

Country Status (13)

Country Link
US (1) US20200129504A1 (cg-RX-API-DMAC7.html)
EP (2) EP3595653B1 (cg-RX-API-DMAC7.html)
JP (3) JP7280192B2 (cg-RX-API-DMAC7.html)
KR (1) KR102659907B1 (cg-RX-API-DMAC7.html)
CN (1) CN110603037A (cg-RX-API-DMAC7.html)
AU (2) AU2018236168B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019018880A2 (cg-RX-API-DMAC7.html)
CA (1) CA3056077A1 (cg-RX-API-DMAC7.html)
DK (1) DK3595653T3 (cg-RX-API-DMAC7.html)
ES (1) ES2942889T3 (cg-RX-API-DMAC7.html)
NZ (2) NZ757213A (cg-RX-API-DMAC7.html)
SG (1) SG11201908420WA (cg-RX-API-DMAC7.html)
WO (1) WO2018169887A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113456643A (zh) * 2021-08-11 2021-10-01 遵义医科大学 一种含普那布林的药物组合及其应用
WO2024078529A1 (zh) * 2022-10-11 2024-04-18 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249052A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗与ras突变相关的癌症的方法
WO2016144636A1 (en) 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CN109475524A (zh) 2016-06-06 2019-03-15 万春药业公司 用于减少中性粒细胞减少症的组合物和方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
GB201713760D0 (en) * 2017-08-28 2017-10-11 Univ Leuven Kath Treatment of epilepsy
WO2019147615A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
US20210161888A1 (en) * 2018-06-01 2021-06-03 Beyondspring Pharmaceuticals, Inc. Composition and method of treating cancer associated with egfr mutation
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
CN113613654B (zh) * 2019-10-15 2024-01-26 大连万春布林医药有限公司 普那布林在制备增加非转移性乳腺癌患者触珠蛋白的药物中的用途
KR20230006568A (ko) * 2020-05-04 2023-01-10 비욘드스프링 파마수티컬스, 인코포레이티드. 낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법
KR102428863B1 (ko) * 2020-08-11 2022-08-03 서울대학교병원 자가면역 뇌염 발생 가능성 예측을 위한 정보 제공 방법
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
US20250152473A1 (en) * 2022-02-10 2025-05-15 Beyondspring Pharmaceuticals, Inc. Stable plinabulin formulations and methods of their preparation and use
WO2025006507A1 (en) * 2023-06-27 2025-01-02 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197344A1 (en) * 2003-08-01 2005-09-08 Palladino Michael A. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CN101237838A (zh) * 2005-06-17 2008-08-06 康宾纳特克斯公司 治疗免疫炎性疾病的联合疗法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
AU2003302721B2 (en) 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
BRPI0506655A (pt) * 2004-02-04 2007-05-08 Nereus Pharmaceuticals Inc dehidrofenilahistinas e seus análogos, e sìntese de dehidrofenilahistinas e seus análogos
WO2007035841A1 (en) * 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2012035436A1 (en) * 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
EP3076972B1 (en) * 2013-10-11 2021-10-06 BeyondSpring, Inc. Cancer treatment with combination of plinabulin and taxane
MX394865B (es) 2015-02-12 2025-03-24 Beyondspring Pharmaceuticals Inc Uso de plinabulina en combinación con inhibidores de punto de control inmunitario
US10912748B2 (en) * 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197344A1 (en) * 2003-08-01 2005-09-08 Palladino Michael A. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CN101237838A (zh) * 2005-06-17 2008-08-06 康宾纳特克斯公司 治疗免疫炎性疾病的联合疗法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
石元凯: "《中国肿瘤内科进展》", 30 June 2016 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113456643A (zh) * 2021-08-11 2021-10-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
WO2024078529A1 (zh) * 2022-10-11 2024-04-18 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Also Published As

Publication number Publication date
EP4190326A1 (en) 2023-06-07
ES2942889T3 (es) 2023-06-07
NZ757213A (en) 2022-01-28
US20200129504A1 (en) 2020-04-30
JP7280192B2 (ja) 2023-05-23
BR112019018880A2 (pt) 2020-04-14
CA3056077A1 (en) 2018-09-20
SG11201908420WA (en) 2019-10-30
AU2024200709A1 (en) 2024-02-22
JP2020520889A (ja) 2020-07-16
AU2018236168B2 (en) 2024-02-29
EP3595653A4 (en) 2020-11-11
KR20190122822A (ko) 2019-10-30
KR102659907B1 (ko) 2024-04-24
AU2018236168A1 (en) 2019-10-10
EP3595653B1 (en) 2023-03-08
JP2023099217A (ja) 2023-07-11
EP3595653A1 (en) 2020-01-22
NZ778329A (en) 2026-03-27
WO2018169887A1 (en) 2018-09-20
DK3595653T3 (da) 2023-04-17
JP2025138849A (ja) 2025-09-25

Similar Documents

Publication Publication Date Title
EP3595653B1 (en) Compositions of plinabulin and use thereof
RU2737496C2 (ru) Способы лечения рака
AU2014207839C1 (en) Androgen receptor modulator and uses thereof
KR20230006568A (ko) 낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법
JP2010510327A (ja) エンドキシフェンの方法および組成物
US20120164211A1 (en) Compositions and methods for treating lymphoma
JP2018518507A (ja) ベルベリン製剤の治療的使用
US20230346716A1 (en) Treatment of skin disorders with topical tapinarof compositions
CN111278436A (zh) 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症
US9381246B2 (en) Cancer therapy
JP2009519250A (ja) リポソーム組成物
US20240189244A1 (en) Compositions and methods for delivering pharmaceutical agents
JP2008542308A (ja) ファルネシルジベンゾジアゼピノン製剤
HK40020654B (en) Compositions of plinabulin and use thereof
HK40020654A (en) Compositions of plinabulin and use thereof
US20240131008A1 (en) topical formulation of Disease-Modifying Antirheumatic Drug (DMARDs) for treatment of rheumatoid arthritis, melanoma, squamous cell carcinoma, atopic dermatitis and psoriasis
WO2024258916A1 (en) Stat3 degraders and uses thereof
CN118317771A (zh) 用于局部治疗布鲁里溃疡中的溃疡分枝杆菌的制剂和方法
HK1108825B (en) Compositions and methods for treating leukemia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination